Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 6;21(1):125.
doi: 10.1186/s12957-023-02888-z.

Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study

Zhen Huang  1 , Zhe Wu  2 , Quan-Qing Zou  1 , Yu-Jie Xie  1 , Li-Hui Li  1 , Yan-Ping Huang  3 , Feng-Ming Wu  3 , Dong Huang  1 , Yin-Hua Pan  1 , Jian-Rong Yang  4
Affiliations

Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study

Zhen Huang et al. World J Surg Oncol. .

Abstract

Background: The randomized trials which include ACOSOG Z0011 and IBCSG 23-01 had found that the survival rates were not different in patients with cT1/2N0 and 1-2 sentinel lymph node (SLN)-positive, macro/micrometastases who underwent breast-conserving therapy, and micrometastases who underwent total mastectomy (TM), when axillary lymph node dissection (ALND) was omitted. However, for patients with cT1/2N0 and 1-2 SLN macrometastases who underwent TM; there was still insufficient evidence from clinical studies to support whether ALND can be exempted. This study aimed to investigate the risk factors of non-sentinel lymph node (nSLN) metastasis in breast cancer patients with 1-2 SLN macrometastases undergoing TM.

Methods: The clinicopathological data of 1491 breast cancer patients who underwent TM and SLNB from January 2017 to February 2022 were retrospectively analyzed. Univariate and multivariate analyses were performed to analyze the risk factors for nSLN metastasis.

Results: A total of 273 patients with 1-2 SLN macrometastases who underwent TM were enrolled. Postoperative pathological data showed that 35.2% patients had nSLN metastasis. The results of multivariate analysis indicated that tumor size (TS) (P = 0.002; OR: 1.051; 95% CI: 1.019-1.084) and ratio of SLN macrometastases (P = 0.0001; OR: 12.597: 95% CI: 4.302-36.890) were the independent risk factors for nSLN metastasis in breast cancer patients with 1-2 SLN macrometastases that underwent TM. The ROC curve analysis suggested that when TS ≤22 mm and ratio of SLN macrometastases ≤0.33, the incidence of nSLN metastasis could be reduced to 17.1%.

Conclusions: The breast cancer patients with cT1/2N0 stage, undergoing TM and 1-2 SLN macrometastases, when the TS ≤22 mm and macrometastatic SLN does not exceed 1/3 of the total number of detected SLN, the incidence of nSLN metastasis is significantly reduced, but whether ALND can be exempted needs further exploration.

Keywords: Breast cancer; Macrometastasis; Non-sentinel lymph node; Risk factor; Sentinel lymph node; Total mastectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Research flow chart. TM, total mastectomy; SLNB, sentinel lymph node biopsy; ITCs, isolated tumor cell clusters; SLN, sentinel lymph node, ALND, axillary lymph node dissection; nSLN, non-sentinel lymph node
Fig. 2
Fig. 2
Receiver operating characteristic (ROC) curve. (Blue line) tumor size, the ROC analysis identified a cut-off point of 22 mm (AUC: 0.625, sensitivity: 60.4%, specificity: 64.4%); (green line) ratio of SLN micrometastases, the ROC analysis identified a cut-off point of 0.33 (AUC: 0.680, sensitivity: 64.6%, specificity: 65.5%)
Fig. 3
Fig. 3
Receiver operating characteristic (ROC) curve of tumor size combined with ratio of SLN micrometastases (AUC: 0.700, sensitivity: 54.2%, specificity: 81.4%)
See this image and copyright information in PMC

References

    1. Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013;7:83–92. doi: 10.1007/s11764-012-0247-5. - DOI - PMC - PubMed
    1. Wong W, Rubenchik I, Nofech-Mozes S, et al. Intraoperative assessment of sentinel lymph nodes in breast cancer patients post-neoadjuvant therapy. Technol Cancer Res Treat. 2019;01:1–6. - PMC - PubMed
    1. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Jama-J Am Med Assoc. 2017;318(10):918–926. doi: 10.1001/jama.2017.11470. - DOI - PMC - PubMed
    1. Galimberti V, Cole BF, Viale G. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385–1393. doi: 10.1016/S1470-2045(18)30380-2. - DOI - PubMed
    1. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–1310. doi: 10.1016/S1470-2045(14)70460-7. - DOI - PMC - PubMed